• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

整合基于配体和靶点驱动的虚拟筛选方法与人类细胞系模型及时间分辨荧光共振能量转移测定法,以鉴定针对BCL-2的新型活性化合物。

Integrating Ligand and Target-Driven Based Virtual Screening Approaches With Human Cell Line Models and Time-Resolved Fluorescence Resonance Energy Transfer Assay to Identify Novel Hit Compounds Against BCL-2.

作者信息

Tutumlu Gurbet, Dogan Berna, Avsar Timucin, Orhan Muge Didem, Calis Seyma, Durdagi Serdar

机构信息

Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahcesehir University, Istanbul, Turkey.

Department of Medical Biology, Bahcesehir University, School of Medicine, Istanbul, Turkey.

出版信息

Front Chem. 2020 Apr 9;8:167. doi: 10.3389/fchem.2020.00167. eCollection 2020.

DOI:10.3389/fchem.2020.00167
PMID:32328476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7160371/
Abstract

Antiapoptotic members of -/-2 (BCL-2) family proteins are one of the overexpressed proteins in cancer cells that are oncogenic targets. As such, targeting of BCL-2 family proteins raises hopes for new therapeutic discoveries. Thus, we used multistep screening and filtering approaches that combine structure and ligand-based drug design to identify new, effective BCL-2 inhibitors from a small molecule database (Specs SC), which includes more than 210,000 compounds. This database is first filtered based on binary " model constructed with 886 training and 167 test set compounds and common 26 toxicity quantitative structure-activity relationships (QSAR) models. Predicted non-toxic compounds are considered for target-driven studies. Here, we applied two different approaches to filter and select hit compounds for further biological assays and human cell line experiments. In the first approach, a molecular docking and filtering approach is used to rank compounds based on their docking scores and only a few top-ranked molecules are selected for further long (100-ns) molecular dynamics (MD) simulations and tests. While docking algorithms are promising in predicting binding poses, they can be less prone to precisely predict ranking of compounds leading to decrease in the success rate of studies. Hence, in the second approach, top-docking poses of each compound filtered through QSAR studies are subjected to initially short (1 ns) MD simulations and their binding energies are calculated via molecular mechanics generalized Born surface area (MM/GBSA) method. Then, the compounds are ranked based on their average MM/GBSA energy values to select hit molecules for further long MD simulations and studies. Additionally, we have applied text-mining approaches to identify molecules that contain "" phrase as many of the approved drugs contain indole and indol derivatives. Around 2700 compounds are filtered based on " model and are then docked into BCL-2. Short MD simulations are performed for the top-docking poses for each compound in complex with BCL-2. The complexes are again ranked based on their MM/GBSA values to select hit molecules for further long MD simulations and studies. In total, seven molecules are subjected to biological activity tests in various human cancer cell lines as well as Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) assay. Inhibitory concentrations are evaluated, and biological activities and apoptotic potentials are assessed by cell culture studies. Four molecules are found to be limiting the proliferation capacity of cancer cells while increasing the apoptotic cell fractions.

摘要

-/-2(BCL-2)家族蛋白的抗凋亡成员是癌细胞中过表达的蛋白之一,是致癌靶点。因此,靶向BCL-2家族蛋白为新的治疗发现带来了希望。于是,我们采用了多步筛选和过滤方法,将基于结构和配体的药物设计相结合,从一个包含超过210,000种化合物的小分子数据库(Specs SC)中识别新的、有效的BCL-2抑制剂。该数据库首先基于用886种训练和167种测试集化合物构建的二元“模型”以及26种常见的毒性定量构效关系(QSAR)模型进行过滤。预测无毒的化合物用于目标驱动的研究。在这里,我们应用了两种不同的方法来过滤和选择命中化合物,以进行进一步的生物学测定和人类细胞系实验。在第一种方法中,使用分子对接和过滤方法根据化合物的对接分数对其进行排名,仅选择少数排名靠前的分子进行进一步的长时间(100纳秒)分子动力学(MD)模拟和测试。虽然对接算法在预测结合姿势方面很有前景,但它们可能不太容易精确预测化合物的排名,从而导致研究成功率降低。因此,在第二种方法中,通过QSAR研究过滤的每种化合物的顶级对接姿势先进行短时间(1纳秒)的MD模拟,并通过分子力学广义玻恩表面积(MM/GBSA)方法计算其结合能。然后,根据化合物的平均MM/GBSA能量值对其进行排名,以选择命中分子进行进一步的长时间MD模拟和研究。此外,我们应用了文本挖掘方法来识别包含“”短语的分子,因为许多已批准的药物都含有吲哚和吲哚衍生物。基于“模型”过滤了大约2700种化合物,然后将其对接至BCL-2。对每种与BCL-2复合的化合物的顶级对接姿势进行短时间MD模拟。再次根据复合物的MM/GBSA值对其进行排名,以选择命中分子进行进一步的长时间MD模拟和研究。总共对七种分子在各种人类癌细胞系以及时间分辨荧光共振能量转移(TR-FRET)测定中进行了生物活性测试。评估抑制浓度,并通过细胞培养研究评估生物活性和凋亡潜力。发现有四种分子在限制癌细胞增殖能力的同时增加了凋亡细胞比例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/424113e930d4/fchem-08-00167-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/2d2ccd0d7ae6/fchem-08-00167-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/9ac86e9fe2bc/fchem-08-00167-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/297a20d8f27b/fchem-08-00167-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/d2cf0c2b0e0f/fchem-08-00167-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/d535408f677b/fchem-08-00167-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/a73aaa1b2038/fchem-08-00167-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/796159f3b76d/fchem-08-00167-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/d335de1afb00/fchem-08-00167-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/118dba8ea269/fchem-08-00167-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/424113e930d4/fchem-08-00167-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/2d2ccd0d7ae6/fchem-08-00167-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/9ac86e9fe2bc/fchem-08-00167-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/297a20d8f27b/fchem-08-00167-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/d2cf0c2b0e0f/fchem-08-00167-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/d535408f677b/fchem-08-00167-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/a73aaa1b2038/fchem-08-00167-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/796159f3b76d/fchem-08-00167-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/d335de1afb00/fchem-08-00167-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/118dba8ea269/fchem-08-00167-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8504/7160371/424113e930d4/fchem-08-00167-g0010.jpg

相似文献

1
Integrating Ligand and Target-Driven Based Virtual Screening Approaches With Human Cell Line Models and Time-Resolved Fluorescence Resonance Energy Transfer Assay to Identify Novel Hit Compounds Against BCL-2.整合基于配体和靶点驱动的虚拟筛选方法与人类细胞系模型及时间分辨荧光共振能量转移测定法,以鉴定针对BCL-2的新型活性化合物。
Front Chem. 2020 Apr 9;8:167. doi: 10.3389/fchem.2020.00167. eCollection 2020.
2
Novel AChE and BChE inhibitors using combined virtual screening, text mining and in vitro binding assays.使用组合虚拟筛选、文本挖掘和体外结合测定法筛选新型 AChE 和 BChE 抑制剂。
J Biomol Struct Dyn. 2020 Jul;38(11):3342-3358. doi: 10.1080/07391102.2019.1660218. Epub 2019 Oct 6.
3
Hybrid and TR-FRET-Guided Discovery of Novel BCL-2 Inhibitors.基于杂交和时间分辨荧光能量共振转移技术指导的新型BCL-2抑制剂的发现
ACS Pharmacol Transl Sci. 2021 Apr 15;4(3):1111-1123. doi: 10.1021/acsptsci.0c00210. eCollection 2021 Jun 11.
4
identification of angiotensin-1 converting enzyme inhibitors using text mining and virtual screening.使用文本挖掘和虚拟筛选鉴定血管紧张素转化酶抑制剂。
J Biomol Struct Dyn. 2022 Feb;40(3):1152-1162. doi: 10.1080/07391102.2020.1827038. Epub 2020 Oct 5.
5
Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline.提出新型 TNFα 直接抑制剂骨架,使用基于片段对接的药效基团模型和基于二元 QSAR 的虚拟筛选协议流水线。
J Mol Graph Model. 2018 Oct;85:111-121. doi: 10.1016/j.jmgm.2018.07.007. Epub 2018 Aug 24.
6
Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.基于片段的 E 药效团虚拟筛选和二元 QSAR 模型靶向 NF-κB/IκBα 复合物。
J Mol Graph Model. 2019 Jan;86:264-277. doi: 10.1016/j.jmgm.2018.09.014. Epub 2018 Oct 5.
7
Screening of FDA approved drugs for finding potential inhibitors against Granzyme B as a potent drug-repurposing target.筛选美国食品和药物管理局批准的药物,寻找潜在的颗粒酶 B 抑制剂,作为一种有潜力的药物再利用靶点。
J Mol Graph Model. 2020 Mar;95:107462. doi: 10.1016/j.jmgm.2019.107462. Epub 2019 Oct 11.
8
Drug Re-positioning Studies for Novel HIV-1 Inhibitors Using Binary QSAR Models and Multi-target-driven In Silico Studies.新型 HIV-1 抑制剂的药物重定位研究:基于二元 QSAR 模型和多靶点驱动的计算研究。
Mol Inform. 2021 Feb;40(2):e2000012. doi: 10.1002/minf.202000012. Epub 2020 Sep 16.
9
Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.基于靶向驱动方法和二元 QSAR 模型,从小分子文库中筛选新型肿瘤坏死因子-α(TNF-α)抑制剂,以评估其治疗类风湿关节炎的活性谱。
J Biomol Struct Dyn. 2019 Jun;37(9):2464-2476. doi: 10.1080/07391102.2018.1491423. Epub 2018 Dec 23.
10
3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.抗结核药物(6S)2-硝基-6-{[4-(三氟甲氧基)苄基]氧基}-6,7-二氢-5H-咪唑并[2,1-b][1,3]恶嗪延长侧链的3D QSAR、对接、分子动力学模拟及MM-GBSA研究
Infect Disord Drug Targets. 2019;19(2):145-166. doi: 10.2174/1871526518666181015145545.

引用本文的文献

1
The Anti-leukemic Activities of Campesterol and Α-Tocopherol Against BCL-2 Target through Computational Drug Design Approaches.通过计算机辅助药物设计方法研究菜油甾醇和α-生育酚对BCL-2靶点的抗白血病活性。
Curr Top Med Chem. 2025;25(7):813-823. doi: 10.2174/0115680266316570240926081647.
2
Predictive identification and design of potent inhibitors targeting resistance-inducing candidate genes from whole-genome sequences.从全基因组序列中预测性鉴定和设计靶向抗性诱导候选基因的强效抑制剂。
Front Bioinform. 2024 Jul 26;4:1411935. doi: 10.3389/fbinf.2024.1411935. eCollection 2024.
3
Natural Compound Dioscin Targeting Multiple Cancer Pathways through its High Affinity Binding to B Cell Lymphoma-2.

本文引用的文献

1
Toward Understanding the Impact of Dimerization Interfaces in Angiotensin II Type 1 Receptor.朝向理解在血管紧缩素 II 类型 1 感受体中的二聚体界面的冲击。
J Chem Inf Model. 2019 Oct 28;59(10):4314-4327. doi: 10.1021/acs.jcim.9b00294. Epub 2019 Sep 13.
2
Refinement and Rescoring of Virtual Screening Results.虚拟筛选结果的优化与重新评分
Front Chem. 2019 Jul 11;7:498. doi: 10.3389/fchem.2019.00498. eCollection 2019.
3
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.BCL-2 与 venetoclax 复合物的结构揭示了耐药突变的分子基础。
天然化合物薯蓣皂苷元通过与B细胞淋巴瘤-2的高亲和力结合靶向多种癌症通路。
Curr Comput Aided Drug Des. 2025;21(5):609-628. doi: 10.2174/0115734099279130231211053542.
4
In silico design and cell-based evaluation of two dual anti breast cancer compounds targeting Bcl-2 and GPER.基于计算机设计和细胞实验评估两种针对 Bcl-2 和 GPER 的双抗乳腺癌化合物。
Sci Rep. 2023 Oct 20;13(1):17933. doi: 10.1038/s41598-023-43860-x.
5
A novel BH3 mimetic Bcl-2 inhibitor promotes autophagic cell death and reduces in vivo Glioblastoma tumor growth.一种新型BH3模拟物Bcl-2抑制剂可促进自噬性细胞死亡并减少体内胶质母细胞瘤肿瘤生长。
Cell Death Discov. 2022 Oct 29;8(1):433. doi: 10.1038/s41420-022-01225-9.
6
The Multistage Antimalarial Compound Calxinin Perturbates Ca Homeostasis by Targeting a Unique Ion Channel.多阶段抗疟化合物卡尔西宁通过靶向一种独特的离子通道扰乱钙稳态。
Pharmaceutics. 2022 Jun 28;14(7):1371. doi: 10.3390/pharmaceutics14071371.
7
Bioactive Phytoconstituents as Potent Inhibitors of Tyrosine-Protein Kinase Yes (YES1): Implications in Anticancer Therapeutics.生物活性植物化合物作为酪氨酸蛋白激酶 Yes(YES1)的有效抑制剂:在癌症治疗中的应用。
Molecules. 2022 May 10;27(10):3060. doi: 10.3390/molecules27103060.
8
Biological Membrane-Penetrating Peptides: Computational Prediction and Applications.生物膜穿透肽:计算预测与应用。
Front Cell Infect Microbiol. 2022 Mar 25;12:838259. doi: 10.3389/fcimb.2022.838259. eCollection 2022.
9
Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease.基于二元定量构效关系指导的针对严重急性呼吸综合征冠状病毒2主要蛋白酶的FDA批准药物及临床研究中的化合物的虚拟筛选
Turk J Biol. 2021 Aug 30;45(4):459-468. doi: 10.3906/biy-2106-61. eCollection 2021.
10
Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study.临床批准药物和研究药物筛选新型冠状病毒 2 型的潜在抑制剂:一项联合计算机筛选和体外研究。
Mol Inform. 2022 Feb;41(2):e2100062. doi: 10.1002/minf.202100062. Epub 2021 Sep 16.
Nat Commun. 2019 Jun 3;10(1):2385. doi: 10.1038/s41467-019-10363-1.
4
Current status of multiscale simulations on GPCRs.GPCRs 的多尺度模拟现状。
Curr Opin Struct Biol. 2019 Apr;55:93-103. doi: 10.1016/j.sbi.2019.02.013. Epub 2019 May 10.
5
Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.基于片段的 E 药效团虚拟筛选和二元 QSAR 模型靶向 NF-κB/IκBα 复合物。
J Mol Graph Model. 2019 Jan;86:264-277. doi: 10.1016/j.jmgm.2018.09.014. Epub 2018 Oct 5.
6
Investigating the molecular mechanism of staphylococcal DNA gyrase inhibitors: A combined ligand-based and structure-based resources pipeline.研究葡萄球菌 DNA 回旋酶抑制剂的分子机制:基于配体和结构的综合资源管道。
J Mol Graph Model. 2018 Oct;85:122-129. doi: 10.1016/j.jmgm.2018.07.010. Epub 2018 Jul 27.
7
Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline.提出新型 TNFα 直接抑制剂骨架,使用基于片段对接的药效基团模型和基于二元 QSAR 的虚拟筛选协议流水线。
J Mol Graph Model. 2018 Oct;85:111-121. doi: 10.1016/j.jmgm.2018.07.007. Epub 2018 Aug 24.
8
Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.基于靶向驱动方法和二元 QSAR 模型,从小分子文库中筛选新型肿瘤坏死因子-α(TNF-α)抑制剂,以评估其治疗类风湿关节炎的活性谱。
J Biomol Struct Dyn. 2019 Jun;37(9):2464-2476. doi: 10.1080/07391102.2018.1491423. Epub 2018 Dec 23.
9
Restoring the switch for cancer cell death: Targeting the apoptosis signaling pathway.恢复癌细胞死亡开关:靶向凋亡信号通路。
Am J Health Syst Pharm. 2018 Jul 1;75(13):945-952. doi: 10.2146/ajhp170607. Epub 2018 May 14.
10
S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.S55746是一种新型的口服活性BCL-2选择性强效抑制剂,可抑制血液肿瘤生长。
Oncotarget. 2018 Apr 13;9(28):20075-20088. doi: 10.18632/oncotarget.24744.